about
Bile acids in regulation of inflammation and immunity: friend or foe?24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver diseaseBile acid-mediated control of liver triglycerides.Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD.Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Liver Capsule: FXR agonists against liver diseaseMetabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury.Hepatocyte specific expression of an oncogenic variant of β-catenin results in lethal metabolic dysfunction in mice.Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice.The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitisFine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver diseaseThyroid hormone receptor β1 stimulates to increase biliary phosphatidylcholine excretion in miceNa -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in miceAbsence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in miceLack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption
P50
Q28066820-B31603CB-D9BA-48FC-9845-38C2F6F9890CQ35201779-7A3DAA6D-E1D4-46BF-ACF4-A7C6B97FA360Q35862141-938A84CE-0136-48B8-AA2F-10DCE2FB3F5FQ37699357-C15899FF-FB2B-4F26-ABAD-404CF1DC57B1Q38162133-65683AEB-7634-4156-AEDF-DE324CB9F050Q38245670-158C70F8-E700-4231-9A1B-5C4BCA055EB6Q38516783-09D0DC82-7852-45C5-A945-B2A4CA5EDB9BQ38730938-93B12760-CFE6-486D-A073-5283D5AFA04DQ38873278-125F1B8B-F306-4C06-8E67-A1FF18762FC9Q39044702-4B8E4AB7-1D93-4DE4-A0C3-9C8F4906B60DQ41654225-9ABA0DA7-9C6D-4149-8B15-0246A76E0D57Q52674797-FD0ABCE7-E770-4CB7-AE36-C834E30C57CBQ52726477-97C2CE91-91DD-4426-8182-196D97411A04Q54327674-29F0842E-0973-402A-AF0D-1D9809A027E4Q55340936-30AB5B14-AA3D-49F3-A6F4-F12C06981429Q57105327-5D8B1604-2229-4F4D-ADB4-1E9699020296Q57108085-769B6EBD-A729-4FED-980A-2AE0590BB63CQ57109925-EA778E7F-AD8E-4798-9508-8B149FD3490EQ57121513-ABB0B0CE-D4F0-4EF7-B7B7-1120DF139866Q90105800-81A203FC-6230-4ABD-B186-4C437FA8FAD3Q91710341-764915FF-A247-4A6D-AFC2-55834B4C93CF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Claudia Fuchs
@ast
Claudia Fuchs
@en
Claudia Fuchs
@es
Claudia Fuchs
@nl
type
label
Claudia Fuchs
@ast
Claudia Fuchs
@en
Claudia Fuchs
@es
Claudia Fuchs
@nl
prefLabel
Claudia Fuchs
@ast
Claudia Fuchs
@en
Claudia Fuchs
@es
Claudia Fuchs
@nl
P106
P31
P496
0000-0002-0636-1320